Trial Profile
Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2021
Price :
$35
*
At a glance
- Drugs Tabalumab (Primary) ; Tabalumab (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Therapeutic Use
- Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd
- 23 Nov 2018 I have updated the locations i.e removed Canada.Checked NCT and Eudra records, results are not specifying locations both Eudra & NCT.
- 29 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Mar 2012 Planned number of patients changed from 245 to 500 as reported by European Clinical Trials Database.